Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, 91-348 Lodz, Poland.
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, 1090 Vienna, Austria.
Int J Mol Sci. 2021 Mar 15;22(6):2964. doi: 10.3390/ijms22062964.
Systemic mastocytosis (SM) is a hematologic neoplasm with abnormal accumulation of mast cells in various organ systems such as the bone marrow, other visceral organs and skin. So far, only little is known about epigenetic changes contributing to the pathogenesis of SM. In the current article, we provide an overview of epigenetic changes that may occur and be relevant to mastocytosis, including mutations in genes involved in epigenetic processes, such as , and , and global and gene-specific methylation patterns in neoplastic cells. Moreover, we discuss methylation-specific pathways and other epigenetic events that may trigger disease progression in mast cell neoplasms. Finally, we discuss epigenetic targets and the effects of epigenetic drugs, such as demethylating agents and BET-targeting drugs, on growth and viability of neoplastic mast cells. The definitive impact of these targets and the efficacy of epigenetic therapies in advanced SM need to be explored in future preclinical studies and clinical trials.
系统性肥大细胞增多症 (SM) 是一种血液系统肿瘤,其特征为肥大细胞在骨髓、其他内脏器官和皮肤等各种器官系统中异常积聚。迄今为止,人们对促成 SM 发病机制的表观遗传变化知之甚少。在本文中,我们概述了可能发生并与肥大细胞增多症相关的表观遗传变化,包括参与表观遗传过程的基因(如 、 和 )中的突变,以及肿瘤细胞中的整体和基因特异性甲基化模式。此外,我们还讨论了可能触发肥大细胞瘤疾病进展的甲基化特异性途径和其他表观遗传事件。最后,我们讨论了表观遗传靶点以及表观遗传药物(如去甲基化剂和 BET 靶向药物)对肿瘤肥大细胞生长和活力的影响。这些靶点的明确作用以及先进 SM 中表观遗传疗法的疗效需要在未来的临床前研究和临床试验中进行探索。